Progress in the Phase 1/2 clinical trial of CTX-712 for blood cancer in the United States
First written in FY2024-Q3. 15 of 17 entries say "Advanced", first in FY2024. Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Enrollment in the U.S. Phase 1/2 trial increased by 4 cases during the second quarter from 38 cases at the end of November 2025, bringing total enrollment to 42 cases as of the end of February 2026. Based on data from these 42 cases, the Safety Evaluation Committee confirmed a dosage and administration regimen meeting the safety and efficacy criteria for transition to an expansion cohort. The expansion cohort is planned as a two-stage program consisting of Initial Expansion (IE) and Additional Expansion (AE), based on the FDA’s Project Optimus guidance. At present, the Phase 2 clinical trial is expected to begin in mid-2027.」
Enrollment in the U.S. Phase 1/2 trial increased from 38 to 42 cases, and the criteria for transitioning to an expansion cohort were confirmed. A two-stage expansion cohort comprising IE and AE is planned, and the Phase 2 trial is expected to begin in mid-2027. - 2026-03-18AdvancedOccurring Fact
「Following these procedures, we have now administered the first dose to the first patient in the expansion cohort.」
In the US Phase 1/2 clinical trial of rogocekib, dosing of the first patient began in the expansion cohort, which had previously been scheduled to start in early 2026. - FY2025AdvancedAnnual report
「As of the end of the fiscal year, we are conducting the Phase 1/2 clinical trial in patients with relapsed or refractory AML and MDS that began in the United States in 2023. As of the end of August 2025, treatment had been completed for 36 patients, and further patient enrollment was under way.」
The number of patients who had completed treatment in the U.S. Phase 1/2 trial increased from 29 at the end of February 2025 to 36 at the end of August 2025. The company also indicated that it plans to begin the expansion cohort in early 2026. - FY2025-H1AdvancedAnnual report
「The Phase 1 portion of the ongoing U.S. Phase 1/2 clinical trial of rogocekib in hematologic cancers is progressing smoothly. 4 patients were added during the second quarter from 25 cases at the end of November 2024, bringing total enrollment to 29 cases as of the end of February 2025.」
Enrollment in the U.S. Phase 1/2 trial in hematologic cancers increased from 25 cases at the end of November 2024 to 29 cases at the end of February 2025. - FY2024AdvancedAnnual report
「As of the end of August 2024, treatment had been completed for 20 patients, and further patient enrollment was under way.」
The number of patients who had completed treatment in the U.S. Phase 1/2 trial increased from 16 previously to 20. - FY2024-Q3First statedAnnual report
「The Phase 1/2 clinical trial in hematologic cancers in the United States is also progressing smoothly. As of the end of May 2024, 16 patients had received treatment, and activities are under way to advance the trial further.」
As of the end of May 2024, 16 patients had received treatment, and the trial is being advanced further.